Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

Immune modulation: translating the benefits The immune system modulating drug sargramostim shows promising results in a small clinical trial with Parkinson’s disease (PD) patients. Previous studies have shown that sargramostim increases the number of regulatory T cells, attenuates immune responses,...

Full description

Saved in:
Bibliographic Details
Main Authors: Howard E. Gendelman, Yuning Zhang, Pamela Santamaria, Katherine E. Olson, Charles R. Schutt, Danish Bhatti, Bhagya Laxmi Dyavar Shetty, Yaman Lu, Katherine A. Estes, David G. Standaert, Elizabeth Heinrichs-Graham, LuAnn Larson, Jane L. Meza, Matthew Follett, Erica Forsberg, Gary Siuzdak, Tony W. Wilson, Carolyn Peterson, R. Lee Mosley
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Neurology. Diseases of the nervous system
RC346-429
Online Access:https://doaj.org/article/ee69bcd53fbd419bb5945c4e0f267aba
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/ee69bcd53fbd419bb5945c4e0f267aba

Similar Items